BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Aug 15, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Esbriet pirfenidone regulatory update

InterMune disclosed in its 2Q11 earnings that in April it launched a named-patient program in major countries of Europe to provide access to Esbriet pirfenidone to treat idiopathic pulmonary fibrosis (IPF) free of charge. The program is expected to last about 12 months. The European Commission approved an MAA for...

Read the full 229 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >